BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
0.8500
-0.0400 (-4.49%)
At close: Nov 6, 2026, 4:00 PM EST
0.8800
+0.0300 (3.53%)
After-hours: Nov 6, 2026, 7:59 PM EST
BioCardia Employees
As of December 31, 2025, BioCardia had 21 total employees, including 17 full-time and 4 part-time employees. The number of employees increased by 1 or 5.00% compared to the previous year. That makes BioCardia the 38,197th largest employer in the world and 5,454th in the United States.
Employees
21
Change (1Y)
1
Growth (1Y)
5.00%
Revenue / Employee
n/a
Profits / Employee
-$349,476
Market Cap
12.87M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | 1 | 5.00% | 17 | 4 |
| Dec 31, 2024 | 20 | 0 | - | 17 | 3 |
| Dec 31, 2023 | 20 | -16 | -44.44% | 16 | 4 |
| Dec 31, 2022 | 36 | 1 | 2.86% | 30 | 6 |
| Dec 31, 2021 | 35 | 6 | 20.69% | 28 | 7 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 138 |
| Fractyl Health | 100 |
| Passage Bio | 24 |
| Daré Bioscience | 24 |
| Lipocine | 14 |
| Radiopharm Theranostics | 14 |
| Tvardi Therapeutics | 12 |
| Psyence Biomedical | 12 |
BCDA News
- 2 days ago - BioCardia completes CardiAMP clinical consultation process with Japan PMDA - TheFly
- 2 days ago - BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application - GlobeNewsWire
- 20 days ago - BioCardia announces FDA acceptance of Helix pre-submission package - TheFly
- 20 days ago - BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter - GlobeNewsWire
- 4 weeks ago - BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting - GlobeNewsWire
- 5 weeks ago - BioCardia files revised de novo pre-submission for FDA approval of Helix - TheFly
- 5 weeks ago - BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter - GlobeNewsWire
- 6 weeks ago - BioCardia provides update on near term milestones for CardiAMP, Helix - TheFly